CrystalLeeMackallMD

Pediatric Hematology & Oncology • Palo Alto, CA

Physician

Join to view full profile

Dr. Mackall is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mackall's full profile

Already have an account?

Office
725 Welch Rd
Palo Alto, CA 94304
Phone+1 650-497-8000

Fax+1 650-497-8959

Education & Training

National Capital ConsortiumFellowship, Pediatric Hematology/Oncology, 1989 - 1992
Akron General Medical Center/NEOMEDResidency, Internal Medicine, 1984 - 1988
Northeast Ohio Medical UniversityClass of 1984

Certifications & Licensure

CA State Medical License 2016 - 2025
OH State Medical License 1984 - 2018
MD State Medical License 1994 - 2017
DC State Medical License 1994 - 1998
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Whos Who in Medicine and Healthcare Marquis Whos Who
Elected Member The American Society for Clinical Investigation, 2005

Clinical Trials

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas Start of enrollment: 1996 Dec 23
Completed
Phase 2
A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas Start of enrollment: 1996 Dec 01
Completed
Phase 2
Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare Diseases Start of enrollment: 1998 Mar 19
Completed
Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy Start of enrollment: 2000 Mar 03
Completed
Phase 1
Surveillance of Fungal Infections in Bone Marrow/Stem Cell and Organ Transplant Recipients Start of enrollment: 2001 Apr 09
Completed
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study Start of enrollment: 2001 Sep 24
Completed
Prognostic Value of a Positive RT-PCR Test in Patients With Ewing Sarcoma Start of enrollment: 2004 Mar 12
Completed
HGS-ETR2 to Treat Children With Solid Tumors Start of enrollment: 2006 Dec 04
Terminated
Phase 1
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma Start of enrollment: 2007 Jun 02
Completed
Phase 1, Phase 2
Enrollment on the Childhood Cancer Research Network (CCRN) of the Children s Oncology Group Start of enrollment: 2010 Apr 30
Terminated
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Start of enrollment: 2012 Sep 27
Completed
Phase 1
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer Start of enrollment: 2007 Oct 01
Completed
Phase 1
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors Start of enrollment: 2014 Feb 28
Completed
Phase 1
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors Start of enrollment: 2016 Dec 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

17 citations
Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy.
Sabina Kaczanowska, Tara Murty, Ahmad Alimadadi, Cristina F Contreras, Caroline Duault
Cancer Cell. 2024-01-08
82 citations
Co-opting signalling molecules enables logic-gated control of CAR T cells.
Aidan M Tousley, Maria Caterina Rotiroti, Louai Labanieh, Lea Wenting Rysavy, Won-Ju Kim
Nature. 2023-03-01
394 citations
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
Robbie G Majzner, Sneha Ramakrishna, Kristen W Yeom, Shabnum Patel, Harshini Chinnasamy
Nature. 2022-03-01

Journal Articles

Fludarabine and Neurotoxicity in Engineered T-cell Therapy
Elliot Norry, Crystal L Mackall, Nature
Tumor Antigen Escape from CAR T-cell Therapy
Crystal L Mackall, Robbie G Majzner, Clinical Cancer Research

Abstracts/Posters

Identification of Dual Positive CD19+/CD3+ T Cells in an Apheresis Product Undergoing Chimeric Antigen Receptor (CAR) Transduction
Crystal L. Mackall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-...
Crystal L. Mackall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Allogeneic Chimeric Antigen Receptor-Invariant Natural Killer T Cells Exert Both Direct and Indirect Antitumor Effects through Host CD8 T Cell Cross-Priming
Crystal L. Mackall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Infectious Complications Associated with CAR T-Cell Therapy
Crystal L. Mackall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy
Crystal L. Mackall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)
Crystal L. Mackall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
CNS Endothelial Cell Activation Emerges as a Driver of CAR T Cell–Associated Neurotoxicity
Crystal Mackall, MD, Clinical Cancer Research, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Plenary
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/3/2019

Press Mentions

Access4Kids: A New Model to Pay for Pediatric Cell and Gene TherapiesAugust 22nd, 2024
Closing the ‘Valley of Death’: Pioneering – and Paying for – New TherapiesJuly 19th, 2024
The Race to Supercharge Cancer-Fighting T CellsJanuary 25th, 2023
Join now to see all

Grant Support

Immunobiology And Immunotherapy Of Pediatric TumorsNational Cancer Institute2011
Biology And Therapy Of LymphopeniaNational Cancer Institute2011
Clinical Program In Pediatric SarcomasNational Cancer Institute2010–2011
Immunobiology Of Pediatric TumorsNational Cancer Institute2010
Developing Immune Based TherapiesNational Cancer Institute2010
Biology Of T Cell DepletionNational Cancer Institute2010
Immunobiology Of Pediatric TumorsDivision Of Basic Sciences - Nci2009
Developing Immune Based TherapiesDivision Of Basic Sciences - Nci2009
Clinical Program In Pediatric SarcomasDivision Of Basic Sciences - Nci2009
Biology Of T Cell DepletionDivision Of Basic Sciences - Nci2009
Developing Immune Based TherapiesNational Cancer Institute2008
Clinical Program In Pediatric SarcomasNational Cancer Institute2008
Biology Of T Cell DepletionNational Cancer Institute2008
Immunobiology And Immunotherapy Of Pediatric TumorsNational Cancer Institute2007
Biology And Therapy Of T Cell DepletionNational Cancer Institute2007
Immunobiology And Immunotherapy Of Pediatric TumorsDivision Of Clinical Sciences - Nci2003–2006
Biology And Therapy Of T Cell DepletionDivision Of Clinical Sciences - Nci2003–2006
Clinical Trials Of Immune Reconstitution/Tumor VaccinatiDivision Of Clinical Sciences - Nci2001–2002
Directing T Cell Responses During Immune ReconstitutionDivision Of Clinical Sciences - Nci1999–2002
Clinical Trials Of Immune Reconstitution/Tumor Vaccination In Pediatric SarcomasDivision Of Clinical Sciences - Nci1999–2000
Directing Immune Responses During Immune ReconstitutionDivision Of Clinical Sciences - Nci1998

CrystalLeeMackallMD

Dr. Mackall is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Grant Support

Viewing the full profile is available to verified healthcare professionals only.